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Crizotinib has been approved for the treatment of advanced ALK-positive nonesmall
cell lung cancer. Its use is associated with the development of complex renal cysts.
However, there is limited literature regarding imaging features of renal cystic disease
during crizotinib therapy and its complications or progression. Here, we describe a
case of a patient with ALK-positive advanced nonesmall cell lung cancer who devel-
oped complex renal cyst during crizotinib treatment. The renal cyst is complicated by
infection and abscess formation. Subsequent renal biopsy, antibiotics treatment, and
open drainage of loculated renal abscess showed no malignant cells and contributed to
the diagnosis. The imaging features should be recognized as renal cystic disease
of crizotinib treatment and not to be mistaken as new metastasis and disease
progression.
© 2016 the Authors. Published by Elsevier Inc. under copyright license from the University
of Washington. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Nonesmall-cell lung cancer comprises of 85% of all lung
cancer diagnosed [1]. The identification of EML4-ALK fusion
gene in 4%-5% of lung adenocarcinoma [2] promotes a new
class of drugs, which selectively targets this subset of
non-small cell lung cancer (NSCLC).
Crizotinib is a first-generation orally active ALK inhibitor,
which received Food and Drug Administration approval forlared that no competing
om (W.Y. Chan).
Elsevier Inc. under copy
se (http://creativecommouse in ALK-positive NSCLC in November 2013. Randomized
control trials report positive progression-free survival and
overall response in patients with disease progression after
conventional chemotherapy. However, recent literature has
reported complication of crizotinib with development of
complex renal cysts [3e5].
Here,wereportimagingfindingsofapatientwithALK-positive
NSCLC who developed complex renal cyst during crizotinib
therapynecessitating opendrainage and cessation of therapy.interests exist.
right license from the University of Washington. This is an open
ns.org/licenses/by-nc-nd/4.0/).
Fig. 1 e Axial CT scan before crizotinib therapy. (A) Right
lung tumor (dotted arrow) and (B) normal kidneys. CT,
computed tomography.
Fig. 2 e CT scan during crizotinib therapy. (A) Significant
decrease in size of right lung tumor and (B) new infected
right kidney middle pole renal cyst (arrow) complicated
by extension to renal pelvis (arrowheads) into the
retroperitoneum with retroperitoneal abscess (*)
11 months after treatment. CT, computed tomography.
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A 68-year-old Asianwomanwas diagnosedwith T2N2M0ALK-
positive lung adenocarcinoma (Fig. 1A). Of note, baseline
computed tomography (CT) demonstrated a 1.4-cm cyst in
segment V of the liver and 2 subcentimeter cysts in the lower
pole of the right kidney but otherwise normal kidneys (Fig. 1B).
She was not suitable for curative surgery or radiotherapy due
to borderline lung function. As part of an ongoing clinical trial,
she was commenced on first-line oral crizotinib tablets. Sub-
sequent chest CT after 2 months of crizotinib demonstrated
partial response of lung tumor (Fig. 2A).
Seven months after initiation of crizotinib, follow-up CT
scan showed 2 new cystic lesions inmiddle and lower poles of
the right kidney. She underwent percutaneous drainage of the
cystic lesions, which was negative for malignancy and infec-
tion, and then commenced on empirical tuberculosis therapy
after consultation with the infectious diseases team. Tuber-
culosis therapy was stopped due to negative cultures, as well
as lack of response. She was admitted again (9 months after
crizotinib initiation) for further drainage, which was onceagain negative for malignancy and infection, and trialled on
various antibiotics as well as antifungals without improve-
ment. In July 2013, her condition deteriorated with extension
of the cysticmasses to her back with fistulation through to the
skin and secondary infection. CT performed showed stable
lung tumor; however, interval increase in size of the retro-
peritoneal loculated septated collection with involvement of
the right posterolateral abdominal wall and psoas muscle
with a lower right posterior back subcutaneous collection
opening to the skin (Fig. 2B). In view of the likely relationship
of crizotinib with renal cysts, and the exclusion of other eti-
ology, crizotinib was discontinued. She eventually underwent
open drainage of these cystic collections. Intraoperatively,
multiloculated abscesses involving the right posterior
abdominal wall, psoas, right posterior liver lobe, and the right
kidney interpolar region were noted. All cultures were nega-
tive, and there was no evidence of malignancy. Postoperative
CT scans demonstrated resolution of the abscess and complex
renal cysts (Fig. 3).
Fig. 3 e CT scan 3 months after stopping crizotinib therapy.
(A) Barely perceivable right lung tumor (dotted arrow) and
(B) interval resolution of right middle pole renal cyst.
Postsurgical drainage and complete resolution of
retroperitoneum abscess is also seen. CT, computed
tomography.
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Crizotinib has been associated with development of renal
cysts [3e5], however, limited literature is available to describe
its progression and imaging features due to novelty of this
class of drug. Although crizotinib is used as a targeted selec-
tive inhibitor of ALK, it is a multikinase inhibitor of c-MET and
ROS1 oncogenic tyrosine kinases. C-MET receptors are nor-
mally present in renal tubular epithelium [6]. It is unknown if
its target of c-MET may explain for crizotinib influence onrenal cysts production, either de novo or increase risk of
complex transformation of existing renal cysts. Further
studies are needed to confirm this hypothesis.
Our case report indicated that these renal cysts can be
complex and complicated by infection, rupture, and abscess
formation. Renal cysts are classified by Bosniak’s category by
their imaging features and complexity [7]. Complex renal
cysts (Bosniak III and IV) are associated with higher malignant
potential and standard guidelines recommend surgery. In this
case, the imaging features are indistinguishable from Bosniak
III lesions, which include cystic renal cell carcinoma or renal
metastasis, which prompts further procedures for histopath-
ologic confirmation.
This case highlights the importance of recognizing the
imaging features of renal cystic disease as a complication
of crizotinib treatment. Erroneous interpretation of such
complex cysts as new metastasis and disease progression
may lead to invasive investigations and patients quality of
life. Isolated case reports in the literature [3,8] suggested
that stopping crizotinib will lead to spontaneous regres-
sion of these renal cysts. Invasive investigative pro-
cedures and surgery, as demonstrated in our case, can be
avoided.r e f e r e n c e s
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